Skip to main content

Web Content Display Web Content Display

Skip banner

Breadcrumb Breadcrumb

Web Content Display Web Content Display

January 2022

20220111
Previous week
Next week

JPIAMR-ACTION Call 2022 - CLOSED

Date: 11.01.2022 - 12.07.2022
JPIAMR-ACTION Call 2022 - CLOSED

Funding institution:

CWN Project Advisor:

Sebastian Bąk,
phone: 12 663 38 46,
e‑mail: sebastian.bak@uj.edu.pl

National Science Centre and JPIAMR

Purpose of the call:

Proposals should focus on licenced antimicrobial agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics:

  • Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)
  • Drug/plant protection agent repurposing;
  • Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
  • Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
  • Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.

Proposals can focus on one or more of the three “One-Health” settings, namely:

  • Human Health, and/or
  • Animal Health (including wildlife, livestock, fishes, and companion animals), and/or
  • Plants (including trees and crops)

The following sub-topics are out of scope of the call:

  • Antiviral and antiparasitic agents
  • Discovery and/or screening of new compounds, new vaccines and/or new targets
  • Proposals solely aiming to develop new diagnostics or new companion diagnostics (companion diagnostics in evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.)

Participation of end-users, stakeholders and companies is encouraged.

Call Timeline:

The call Disrupting drug resistance using innovative design will follow a two-step evaluation procedure.

  • 8 March 2022 (14.00 CET) – Deadline pre-proposals
  • 5 July 2022 – Deadline full proposals

More information:

Call announcement